DOCSLIB.ORG

Nclassified United States Internationaldevelopment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nclassified United States Internationaldevelopment NCLASSIFIED UNITED STATES INTERNATIONALDEVELOPMENT COOPERATION AGENCY AGENCY FOR INTERNATIONAL DEVELOPMENT Washington, D. C. 20523 GRENADA PROJECT PAPER RELIEF AND RECONSTRUCTION (and Amendment # 1) kj AID/LAC/P-234 Project Number:543-0010 UNCLASSIFIED AGENCY FOR INTERNAT'ONAL tUCVLOpMENT ITRANSACT.A.dm O CODE ,I ' ' E PROJECT DATA SHEET AC-Cag COUNTRY ",,TY"' GRENADA I 3..PROJECTPO43-0010 . B,.lE R" BURE.':R. P ,5. PROJECTTIrLE *.-,amu,. 0 .hn:ct,. Latin ''rican and the Caribbean. 5L J9L]enada Mental Health Serviu:' :i.ct c, 6. PROJECT .\SI .:CE COMPLETION DATE (PACD) 7. ESTLMATED DATE O F OBLI GAIION (Under 'B'below, enter 1. 2. J, or 4) N5M1 DD YY l 310 8161 A.initiaFYLjJ HQatL C. Final r L8 L9j 8,CO5T, (1000 OR EQUIVALENT 51 = A. FUNDING SOURCE FIRST FY f5 LIFE OF PROJ ECr_... B. FX C. L/C D. Total E. FX AMD App~ropriated Total F. L/C G. T t-d 790 10 son 2,2 62 1,000 -_ 3, 2.6 (Grant) ESF ( 790 ) goo(0 2,262 1 ,(000 13 2 62 (Loan) ( ) ( )( ) ( ) _ _ _ __, Other , U.5- 2. Host Counuy LWn__n 784 8_ Other Donor(s) _ _ _ _ TOTAL S _ 790 430 1,220 2 21,74 4,046. 9. SCHEDULE OF AID FUNDING (SOOO) -P.LPRB. B.A R C. PRDARY ­ E A. APPRO. PRIMARY TECH. CODE D. OBLIG,%rIONs 0oDArE E. AMOUNT APPROVED F. LIFE OF PROJECT PRO PU.AT .. ... THIS ACTION CODE 1.Grant 2. Loan I. Grant 2. Loan 1. Grant 2. Loan I. rant 2. L.., ESP.. 0 800 3,262 _ (2) (4) i _ TOTALS 0 800 3, 10. SECONDARY TECHNICAL CODES (maximum 6 codes o 3 poitions each) 11. SECONDAY\ I "i ISE CO! 12. SPECIAL CONCERNS CODES (maximum 7 code of 4 positions each) A.Code II B. Amount . 13. PROJECT PURPOSE (maximum 4180 characters) The Project purpose is to assist the Ministry of Health (Moll) oi Grenada in the construction of an inpatient psychiatric facility to replace the destroyed Richmond Hill Mental Hospital and to up-grade the MOH capacity to best utilize the new facility within the existing hospital and community based mental health services delivery system. 14. SCHEDULED EVALUATIONS 15. SOURCE/ORIGIN OF GOODS AND SERVICES NM YY 1 1 MM1 fl' %M YY Interimj01418161 1 Rn-ali !01118171 I3 000 941 Local E3 Othr(Siec j 16. AMENDMENTS/NATURE OF CHANGE PROPOSED (Thu it page I of a page PP Amendment) plgatur IA A " - El I W-. 17. APPROVED Jame -7-tT/aY .­e Lc'"Q. c IN .,iW , .. ,,, 'w r' , D ae Si11ea BY ite Director . DD Y.[M DD YY Regional Development Office/Cbean,. Sie T %W130 (6.74r AGENCY FOR INTERNATIONAL DEVt-LOPMENT 1. TRANSACTION CODE DOCUMENT ,E A= Add Amendment Number CODE PROJECT DATA SHEET C =Change 1L D = Delete 3 2.COUNTRY/ENTITY 3.PROJECT NUMBER Grenada 543-0010 4. BUREAU/OFFICE 5. PROJECT TITLE (maximum 40 chaacters) Latin America and the CaribbeanI [:5 -I Delief and Reconstruction ­ 6. PROJECT ASSISTANCE COMPLETION DATE (PACD) 7. ESTIMATED bATE OF OBLIGATION (Under B.' below, enter 1. Z 3,or4) MM DD YY 1111131018161 A.InitialFY L8Ls! B.QuarterM ~ c. FinalFY 18151 8.COSTS (1000 OR EQUIVALENT SI = A. FUNDING SOURCE FIRST FY 85 LIFE OF PROJECT B. FX C. L/C D. Total E. FX F. L/C G. Total AID Appropriated Total 1,800 2,100 3U9U 1P800 2,100 3,900 (Gat 0 (Grant) ( 1.800 ) ( 2,100)J( 3,900 2,100) ( 1,800 3,0) ( 2,100 ) ( 3,900 (Loan) ( )( )( )( )( ) _( _ ) Other I1. U.S. 2. Host Country 420 420 784 784 Other Donor(s) TOTAL S 1.0 0 2,520 4,320 1,800 2,884 4,684 9.SCHEDULE OF AID FUNDING ($000) B. c. PRIMARY A. APPR PRIMARY TECH. CODE D.OBLIGATIONS TO DATE E.AMOUNT APPROVED F.LIFE OF PROJECT PRIATION PURPOSE -__________ THIS ACTION CODE l.Grant 2.Loan 1.Grant 2.Loan 1.Grant 2.Loan 1.Grant 2.Loan (I) ESF 520 580 800 - 3,100 3,900 ­ (2) (4) TOTALS -7 800 - 3,100 - 900­ 10. SECONDARY TECHNICAL CODES (maximum 6 codes of3 positions each) i11. SECONDARY PURPOSE CODE 510 I 11 1 1 530 12. SPECIAL CONCERNS CODES (maximum 7 codes sf4 positionseach) A.Code I I B. Amount 13. PROJECT PURPOSE (maximum 480 characters) The purpose of the Grenada Mental Health Services sub-project is to assist the Ministry of Health (MOH) of Grenada in the construction of an inpatient facility to replace the damaged Richmond Hill Mental Health Facility and to up-grade the MOH capacity to best utilize the new facility within the existing hospital and community based mental health services delivery system. 14. SCHEDULED EVALUATIONS 15. SOURCE/ORIGIN OF GOODS AND SERVICES MM I YY MM Yy MM YY Interim 10143161 1 1 1 Final ]01187 1 D 941 Local [K] other(specify) 935 16. AMENDMENTS/NATURE OF CHANGE PROPOSED (This is page 1 of a pagePPAmendmen) This action provides funding for Phase II (construction) of the Grenada Mental Health Services sub-project. Si t ! .1/8. DATE DOCUMENT RECEIVED 17. I IN AID/W, OR FOR AID/W DOCU­ 17. APPROVED Dat MENTS, DATE OF DISTRIBUTION BY TiI Dat Signed Director, RDO/C MM DD YY MM DD YY AM 1330.4 (5.79) PROJECT AUTHORIZATION Name of Country: Grenada Name of Project: Relief and Reconstruction/Grenada Mental Health Services, Phase I Number of Project: 543-0010(A) 1. Pursuant to Section 531 of the Foreign Assistance Pit of 1961, as amended, I hereby authorize the Relief and Reconstruction/Grenada Mental Health Services Project for Grenada (the "Grantee") involving planned obligations not to exceed eight hundred thousand United. States Dollars (US$800,000) in grant funds ("Grant") over a thirty month period from the date of authorization, subject to the availability of funds in accordance with the A.I.D. OYB/allotment process, to help in financing foreign exchange and local currency costs for the Project. 2. The Project consists of assistance to the Grantee in a program to provide funds for improvement in the effective delivery of mental health services to the Grenadian population. Specifically, the Project is designed to : (a) assist the Ministry of Health (MOH) in the design of an inpatient psychiatric facility to replace the destroyed Richmond Hill Mental Hospital; and (b) upgrade the MOH institutional capacity to best utilize the facility within the existing hospital and community-based mental health services delivery system. Support will include resources for: (1) designing the mental health replacement facilities; (2) improvement of community mental health services; and (3) pharmaceutical procurement and administration. The Project will also fund short and long term technical assistance for staff development. 3. The Project Agreement, which may be negotiated and executed by the officer to whom such authority is delegated in accordance with A.I.D. regulations and Delegations of Authority, shall be subject to the following essential terms and covenants and major conditions, together with such other terms and conditions as A.I.D. may deem appropriate. A. Source and Origin of Goods and Services Except for ocean shipping, and except as set forth in Section D below, goods and services financed by A.I.D. under the Project shall have their source and origin in the United States and Grenada. Ocean shipping financed by A.I.D. under the Project shall be procured in the United States, except as A.I.D. may otherwise agree in writing. - 2 - B. Conditions Precedent to Disbursement (1) First Disbursement. Prior to the first disbursement under the Grant, or to the issuance by A.I.D. of documentation pursuant to which disbursement will be made, the Grantee will, except as the parties may otherwise agree in writing, furnish to A.I.D. in form and substance satisfactory to A.I.D.: (a) An opinion of counsel satisfactory to A.I.D. that the Agreement has been duly authorized and/or ratified by, and executed on behalf of, the Grantee, and that it constitutes a valid and legally binding obligation of the Grantee in accordance with all of its terms; (b) A statement of the name of the person holding or acting in the office of the Grantee specified as a representative, and of any additional representatives, together with a speciman signature of each person specified in such statement. (c) Evidence of adequate arrangements securing title to the land identified for building of the replacement facilities. (2) Disbursement In Excess of $100 000: Prior co any disbursement under the Grant, or to the issuance by A.I.D. of documentation pursuant to which disbursement will be made, in excess of $100,000, the Grantee shall appoint a Ministry of Health official, or other appropriate GOG official, as Project Administrator responsible for the execution and coordination of all Project activities. C. Covenants Except as A.I.D. may agree otherwise in writing, the GOG shall: (1) Assign the requisite management and technical staff to adequately carry out the Project objectives at all levels; (2) Make staff available for training in accordance with the training plan which is part of this Project; (3) Establish and budget a full-time psychiatrist position in the MOH to serve the needs of the Treatment and Rehabilitation, Acute Psychiatric Care Unit, and community mental health services; (4) Reduce the number of patients at the Richmond Hill Mental Hospital before site preparation begins and continue to discharge patients to be maintained in the community through the - 3 ­ community health services until the number of inpatients at the Richmond Hill Mental Hospital is reduced to a level that can be maintained at the new Treatment and Rehabilitation Center; (5) Establish and budget for additional positions in order to provide adequate inpatient services in both the Acute Psychiatric Care Unit and the Treatment and Rehabilitation Center, as well as outpatient services in the districts; (6) Provide General Hospital patient services such as laundry, food, X-rays, laboratory, and pharmaceuticals adequate for the Acute Psychiatric Care Unit; (7) Provide the budget necessary to finance the recurrent costs of the Acute Care and Treatment and RehabilitaLion f'acilities for the Life of the Project.
Load more

Recommended publications
  • Commentary USP 40–NF 35
    Commentary USP 40–NF 35 November 1, 2016 In accordance with USP’s Rules and Procedures of the Council of Experts (“Rules”) and except as provided in Section 7.02 Accelerated Revision Processes, USP publishes proposed revisions to the United States Pharmacopeia and the National Formulary (USP–NF) for public review and comment in the Pharmacopeial Forum (PF), USP’s free bimonthly journal for public notice and comment. After comments are considered and incorporated as the Expert Committee deems appropriate, the proposal may advance to official status or be re-published in PF for further notice and comment, in accordance with the Rules. In cases when proposals advance to official status without re-publication in PF, a summary of comments received and the appropriate Expert Committee's responses are published in the Revisions and Commentary section of the USP website at the time the official revision is published. The Commentary is not part of the official text and is not intended to be enforceable by regulatory authorities. Rather, it explains the basis of Expert Committees’ responses to public comments on proposed revisions. If there is a difference between the contents of the Commentary and the official text, the official text prevails. In case of a dispute or question of interpretation, the language of the official text, alone and independent of the Commentary, shall prevail. For further information, contact: USP Executive Secretariat United States Pharmacopeia 12601 Twinbrook Parkway Rockville, MD 20852-1790 USA [email protected] Page 1
    [Show full text]
  • Oxford® Policy Update Bulletin: October 2015 Oxford
    Oxford October 2015 policy update bulletin Medical & Administrative Policy Updates UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Policy Update Bulletin was developed to share important information regarding Oxford® Medical and Administrative Policy updates.* *Where information in this bulletin conflicts with applicable state and/or federal law, Oxford® follows such applicable federal and/or state law Oxford Oxford® Medical and Administrative Policy Updates Overview This bulletin provides complete details on Oxford® Medical and Policy Update Classifications Administrative Policy updates. The appearance of a service or New procedure in this bulletin indicates only that Oxford® has recently New clinical coverage criteria and/or documentation review requirements adopted a new policy and/or updated, revised, replaced or have been adopted for a service, procedure, test, or device retired an existing policy; it does not imply that Oxford® provides Updated coverage for the service or procedure. In the event of an An existing policy has been reviewed and changes have not been made inconsistency or conflict between the information provided in this to the clinical coverage criteria or documentation review requirements; bulletin and the posted policy, the provisions of the posted policy however, items such as the clinical evidence, FDA information, and/or will prevail. Note that most benefit plan documents exclude from list(s) of applicable codes may have been updated benefit coverage health services identified as investigational or unproven/not medically necessary.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 1-15182 DR. REDDY’S LABORATORIES LIMITED (Exact name of Registrant as specified in its charter) Not Applicable TELANGANA, INDIA (Translation of Registrant’s name (Jurisdiction of incorporation or into English) organization) 8-2-337, Road No. 3, Banjara Hills Hyderabad, Telangana 500 034, India +91-40-49002900 (Address of principal executive offices) Saumen Chakraborty, Chief Financial Officer, +91-40-49002004, [email protected] 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India (Name, telephone, e-mail and/or facsimile number and address of company contact person) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of Each Class Name of Each Exchange on which Registered American depositary shares, each New York Stock Exchange representing one equity share Equity Shares* * Not for trading, but only in connection with the registration of American depositary shares, pursuant to the requirements of the Securities and Exchange Commission.
    [Show full text]
  • Compendial Approvals for USP40-NF35
    Compendial Approvals for USP40-NF35 Category Monograph Title Monograph Section Scientific Liaison New <89.1> COLLAGENASE I PF 41(5) Pg. ONLINE Introduction, DEFINITION/Introduction, IDENTIFICATION/A., Edith Chang IDENTIFICATION/B., ASSAY/Procedure, PURITY/Procedure, IMPURITIES/Clostripain Activity/Potassium phosphate buffer, IMPURITIES/Clostripain Activity/Dithiothreitol solution, IMPURITIES/Clostripain Activity/Calcium chloride solution, IMPURITIES/Clostripain Activity/Substrate stock solution, IMPURITIES/Clostripain Activity/Substrate solution, IMPURITIES/Clostripain Activity/Sample solution, IMPURITIES/Clostripain Activity/Instrumental conditions, IMPURITIES/Clostripain Activity/Analysis, IMPURITIES/Clostripain Activity/System suitability, IMPURITIES/Clostripain Activity/Acceptance criteria, IMPURITIES/Trypsin Activity/Buffer, IMPURITIES/Trypsin Activity/Substrate stock solution, IMPURITIES/Trypsin Activity/Substrate solution, IMPURITIES/Trypsin Activity/Sample solution, IMPURITIES/Trypsin Activity/Instrumental conditions, IMPURITIES/Trypsin Activity/Analysis, IMPURITIES/Trypsin Activity/System suitability, IMPURITIES/Trypsin Activity/Acceptance criteria, SPECIFIC TESTS/Protein Content, SPECIFIC TESTS/Bacterial Endotoxins Test <85>, SPECIFIC TESTS/Microbial Enumeration Tests <61>, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/Labeling, ADDITIONAL REQUIREMENTS/USP Reference Standards <11> New <89.2> COLLAGENASE II PF 41(5) Pg. ONLINE Introduction, DEFINITION/Introduction, IDENTIFICATION/A., Edith Chang IDENTIFICATION/B.,
    [Show full text]
  • Oxford® Policy Update Bulletin: June 2016
    June 2016 policy update bulletin Medical & Administrative Policy Updates UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Policy Update Bulletin was developed to share important information regarding Oxford® Medical and Administrative Policy updates.* *Where information in this bulletin conflicts with applicable state and/or federal law, Oxford® follows such applicable federal and/or state law Oxford® Medical and Administrative Policy Updates Overview This bulletin provides complete details on Oxford® Medical and Policy Update Classifications Administrative Policy updates. The appearance of a service or New procedure in this bulletin indicates only that Oxford® has recently New clinical coverage criteria and/or documentation review requirements adopted a new policy and/or updated, revised, replaced or have been adopted for a service, procedure, test, or device retired an existing policy; it does not imply that Oxford® provides Updated coverage for the service or procedure. In the event of an An existing policy has been reviewed and changes have not been made inconsistency or conflict between the information provided in this to the clinical coverage criteria or documentation review requirements; bulletin and the posted policy, the provisions of the posted policy however, items such as the clinical evidence, FDA information, and/or will prevail. Note that most benefit plan documents exclude from list(s) of applicable codes may have been updated benefit coverage health services identified as investigational or unproven/not medically necessary.
    [Show full text]
  • Keeping Families Safe Around Medicine March 2014 of Every Day, a Poison Control Center Answers a Call Every Minute About a Young Child Getting Into Medicine
    Keeping Families Safe Around Medicine March 2014 of every day, a poison control center answers a call Every minute about a young child getting into medicine. Nearly 500,000 calls per year. In 2012, more than 64 ,000 kids were treated in an That’s one child every 8 minutes. emergency room for medicine poisoning. Whose medicine are they getting into? 77% In 3 out of 4 of these cases, the medicine belonged to a parent or grandparent. 39% + 38% parents grand- parents The “typical” household is changing Older adults are taking with more grandparents in the home. more medicine. Older adults make up 13% of the population 23% increase 34% in the number of grand- but account for 34% of 13% parents living with their prescription medicine use. grandchildren since 2005. 74% of grandparents 1 in 8 say they take a prescription grandparents provide care on a regular medicine every day. basis for a grandchild. So kids are around more medicine than ever before. Where are grandparents storing medicine that kids might get into? Among those who use easy-open containers, 42% keep prescrip- 12% 28% tion medicine of grandparents who take keep their medicines in on a bathroom care of their grandkids every easy-open containers or kitchen sink, day keep prescription medicine or bottles without a counter, table on a nightstand or dresser. child-resistant cap. or shelf. What are they worried about? More grandparents But 3 6 times identified electrical more children go to outlets than medicine the ER for medicine as a top safety issue.
    [Show full text]
  • SECTION 1: History and Scope of the Pharmacy Technician
    SECTION 1: History and Scope of the Pharmacy Technician Scope of the Pharmacy Technician Section 1 Quiz — Check Your Knowledge Section 1 — Quiz Answers SECTION 2: Manufacturing Pharmaceuticals Section 2 Quiz — Check Your Knowledge Section 2 — Quiz Answers SECTION 3: Rules and Regulations (PTCB 2.0) Omnibus Budget Reconciliation Act of 1990 (OBRA ’90)(PTCB 2.9) Poison Prevention Packaging Act of 1970 (PPPA) Health Insurance Portability and Accountability Act (HIPAA) (PTCB 2.8) Combat Methamphetamine Epidemic Act of 2005 (CMEA) Manufacturer Drug Package Labeling Repackaging Medications (PTCB 2.12) Therapeutic Equivalence (PTCB 1.2) Section 3 Quiz — Check Your Knowledge Section 3 – Quiz Answers SECTION 4: Controlled Substances (PTCB 2.4) Schedule for Controlled Substances Forms Required for Storing, Maintaining and Distributing Controlled Substances(PTCB 2.3, 2.4) Storage and Record Keeping for Controlled Substances Prescribing and Filling Rules and Regulations for Controlled Substances Prescribing Rules for Schedule C-III to C-V Medications for Treatment of Addiction (buprenorphine) Validating Prescribers Section 4 Quiz — Check Your Knowledge Section 4 – Quiz Answers SECTION 5: Pharmacy Safety Storage and Handling of Hazardous Substances (PTCB 2.1, 2.2) Hazardous Drugs – Drugs That Can Have Very High Risk Side Effects Restricted Drug Programs(PTCB 2.7) Frequently Used REMS System for Thalidomide Education and Prescribing Safety Medication Safety (PTCB 4.3) Look Alike – Sound Alike Medications (PTCB 4.4) Common Drug Interactions (PTCB 1.3)
    [Show full text]
  • Pharmacists' Pharmacopeia
    3 Pharmacists’ Pharmacopeia Official May 1, 2009 – August 1, 2009 USP Pharmacists’ Pharmacopeia Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Pharmacists’ Pharmacopeia of a monograph on any drug in respect to which pat- ent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express per- mission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Pharmacists’ Pharmacopeia Text Use of the USP Pharmacists’ Pharmacopeia is subject to the terms and conditions of the USP Pharmacists’ Pharmacopeia License Agreement. Attention is called to the fact that USP Pharmacists’ Pharmacopeia text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2009 The United States Pharmacopeial Convention ISSN: 1930-2908 ISSN online: 1930-2916 © 2009 USP 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. S3/ii USP Pharmacists’ Pharmacopeia Contents USP Pharmacists’ Pharmacopeia Section 1— Section 8— Mission and Preface . S3/1 Dietary Supplement Monographs and General Chapters . S3/72 Section 2— General Notices and Requirements . S3/9 Section 13— Reference Tables of USP–NF . S3/76 Section 3— Drug Substance and Compounded Preparation Index . S3/130 Monographs . S3/22 Section 7— Pharmacy-Related General Chapters .
    [Show full text]
  • Neurodegeneration Product Guide | Edition 2
    Neurodegeneration Product Guide | Edition 2 Passion Flower Passiflora caerulea A source of Harmane Contents by Research Area: • Neurodegeneration • Alzheimer’s Disease • Parkinson’s Disease • Huntington’s Disease Tocris Product Guide Series Neurodegeneration Research Contents Page Neurodegeneration 3 Alzheimer’s Disease 5 Parkinson’s Disease 12 Huntington’s Disease 17 List of Acronyms 23 Neurodegeneration Research Products 24 Further Reading 34 Introduction Neurodegenerative diseases are highly prevalent disorders for which the greatest risk factor is increasing age. The pathogenesis of these disorders is yet to be fully understood, and current research efforts are focused on elucidating the cellular and molecular mechanisms responsible, with the hope that drugs that prevent or reverse disease progres- sion will be discovered. Three of the major neurodegenerative diseases are Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, which are discussed in this product guide. Research into these disorders has so far yielded few drugs that have proven effective in clinical trials, and many current therapies are targeted at attenuating disease symptoms, rather than disease progression. Due to the prevalence of neurodegenerative diseases, they constitute a significant human, societal and economic burden. The global financial cost far outweighs other disorders such as stroke, musculoskeletal disease, heart disease or cancer. Given the aging population, the incidence of neurodegenerative disorders is predicted to rise; early diagnosis and effec- tive treatment is of paramount importance, and these rely on a greater understanding of the mechanisms that underlie each disorder. Included in this guide are key compounds used in the study of Alzheimer’s, Parkinson’s and Huntington’s disease, as well as illustrative schematics of the molecular mechanisms thought to contribute to each disease.
    [Show full text]
  • WO 2013/163455 A2 31 October 2013 (31.10.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/163455 A2 31 October 2013 (31.10.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/415 (2006.01) A61K 31/395 (2006.01) kind of national protection available): AE, AG, AL, AM, A61P 25/00 (2006.01) C12Q 1/68 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 13/038260 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 25 April 2013 (25.04.2013) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/638,043 25 April 2012 (25.04.2012) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: THE REGENTS OF THE UNIVERSITY GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, OF CALIFORNIA [US/US]; Office Of The President, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 111 Franklin Street, 5th Floor, Oakland, CA 94607-5200 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (US).
    [Show full text]
  • Modeling the Binding of Inhibitors/Drugs to the Human Serotonin Transporter Kalyan Immadisetty
    Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Spring 2015 Modeling the Binding of Inhibitors/Drugs to the Human Serotonin Transporter Kalyan Immadisetty Follow this and additional works at: https://dsc.duq.edu/etd Recommended Citation Immadisetty, K. (2015). Modeling the Binding of Inhibitors/Drugs to the Human Serotonin Transporter (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/678 This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact [email protected]. MODELING THE BINDING OF INHIBITORS/DRUGS TO THE HUMAN SEROTONIN TRANSPORTER A Dissertation Submitted to the Bayer School of Natural and Environmental Sciences Duquesne University In partial fulfillment of the requirements for the degree of Doctor of Philosophy By Kalyan Immadisetty May 2015 Copyright by Kalyan Immadisetty 2015 MODELING THE BINDING OF INHIBITORS/DRUGS TO THE SEROTONIN TRANSPORTER By Kalyan Immadisetty Approved April 8, and 2015 ________________________________ ________________________________ Jeffry D. Madura, Ph.D. Jeffrey D. Evanseck, Ph.D. Professor of Chemistry and Biochemistry Professor of Chemistry and Biochemistry (Committee Chair) (Committee Member) ________________________________ ________________________________ David W. Seybert, Ph.D. Christopher K. Surratt, Ph.D.
    [Show full text]
  • Identifying and Controlling Poisons of the Nervous System
    Neurotoxicity: Identifying and Controlling Poisons of the Nervous System April 1990 OTA-BA-436 NTIS order #PB90-252511 Recommended Citation: U.S. Congress, Office of Technology Assessment, Neurotoxicity: Identifying and Controlling Poisons of the Nervous System, OTA-BA-436 (Washington, DC: U.S. Government Printing Office, April 1990). For sale by the Superintendent of Documents U.S. Government Printing Office, Washington, DC 20402-9325 (order form can be found in the back of this report) . Foreword Extraordinary developments in the neuroscience in recent years have been paralleled by a growing congressional interest in their policy implications. The designation of the 1990s by the 101st Congress as the “Decade of the Brain” is one indication of the promise shown by scientific advances for treating diseases of the nervous system and for increased general understanding of the human mind. Other advances, however, have led us to the disturbing realization that many commonly used chemicals can adversely affect the human nervous system. Concern about this issue provided the motivation for hearings held in October 1985 on ‘‘Neurotoxins in the Home and in the Workplace’ by the Subcommittee on Investigations and Oversight of the House Committee on Science and Technology. Another result of heightened congressional interest was a request that OTA undertake a series of assessments on major public policy issues related to the neuroscience. Requesting committees included the House Committees on Science, Space, and Technology; Energy and Commerce; Appropriations; and Veterans’ Affairs; and the Senate Subcommittee on Science, Technology, and Space of the Committee on Commerce, Science, and Transportation. In addition, the Senate Committee on Environment and Public Works recently requested a study of the noncancer health risks posed by toxic substances.
    [Show full text]